论文部分内容阅读
目的 研究原发性肝癌患者肝动脉化疗栓塞术前后血清IL -12和sTNFR -Ⅰ水平的变化及其临床意义。方法 采用双抗体夹心酶联免疫法 (ELISA) ,检测 60例中晚期肝癌患者肝动脉化疗栓塞术前后血清IL -12和sTNFR -Ⅰ水平的改变 ,并与健康对照组比较。结果 肝癌组治疗前IL -12水平降低 ,sTNFR -Ⅰ水平升高 ,与对照组比较有非常显著性差异 (P <0 .0 1) ;肝动脉化疗栓塞术后 ,患者血清IL -12水平升高 ,sTNFR -Ⅰ水平降低 ,治疗前后比较有非常显著性差异 (P <0 .0 1) ;应用免疫调节剂组较未应用组血清IL -12水平升高和sTNFR -Ⅰ水平下降更显著。结论 检测原发性肝癌患者血清IL -12和sTNFR -Ⅰ的水平 ,有助于了解患者的免疫状况 ,肝动脉化疗栓塞术能改善患者机体免疫功能 ,给予合理的过继免疫治疗能增强这种作用
Objective To study the changes of serum IL-12 and sTNFR-Ⅰ levels in patients with primary liver cancer before and after transcatheter arterial chemoembolization and its clinical significance. Methods Serum levels of IL-12 and sTNFR-Ⅰ in 60 patients with advanced hepatocellular carcinoma before and after transcatheter arterial chemoembolization (TACE) were measured by double antibody sandwich enzyme-linked immunosorbent assay (ELISA) and compared with healthy controls. Results The level of IL-12 and the level of sTNFR-Ⅰ in HCC group before treatment were significantly higher than those in control group (P <0.01). The level of IL-12 in patients with HCC was significantly lower than that in control group High, sTNFR-Ⅰ levels decreased significantly before and after treatment compared with the significant difference (P <0.01); application of immunomodulator group than the non-application group, serum IL-12 levels and sTNFR-Ⅰ levels decreased more significantly. Conclusion Detecting serum levels of IL-12 and sTNFR-I in patients with primary liver cancer is helpful to understand the immune status of patients. Transcatheter arterial chemoembolization can improve the immune function of patients and the reasonable adoptive immunotherapy can enhance this effect